Olaparib

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 10, 2024
DNA replication, PARP1, Olaparib, PARG, CRISPR, PARP, HR, IC50, ADME, DNA, Chromatin, PDD, San Diego Convention Center, FEN1, DNA repair, DDR, EC50, Blacksmith, Niraparib, Erosion (morphology), AACR, ATR, Drug discovery, USP1, SAN, Pharmaceutical industry

"Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."

Key Points: 
  • "Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."
  • The Blacksmith fragment-based drug discovery platform identified a novel metal-binding pharmacophore that binds to the two magnesium ions in the FEN1 active site.
  • Further elaboration using fragment growth strategies resulted in highly potent and selective inhibitors.
  • Title: "Small molecule inhibitor of FEN1 nuclease utilizing a novel metal binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR"

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023
Principal, Real, AstraZeneca, Breast cancer, Patient, Cancer, Olaparib, Health, RWE, Pharmaceutical industry, Medical device, PX

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App

Retrieved on: 
Thursday, December 7, 2023
Principal, Real, AstraZeneca, Breast cancer, Patient, Cancer, Olaparib, Health, RWE, Pharmaceutical industry, Medical device, PX

LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
  • The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
  • Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
  • With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, ESMO, Progression-free survival, Congress, Endometrial cancer, PFS, HIV disease progression rates, Journal, Risk, American Journal of Clinical Oncology, Olaparib, European Society of Gynaecological Oncology, European Society for Medical Oncology, Patient, Death, Pharmaceutical industry

Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Key Points: 
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated hypophysitis occurred in 1.3% (8/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.5%) adverse reactions.
  • Real-World Outcomes in Patients with Advanced Endometrial Cancer: A Retrospective Cohort Study of US Electronic Health Records.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, May 9, 2023
Other Health, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Sherpa, Pancreatic cancer, Computational biology, Patent, US Foods, DNA, Human, Brain, AACR, Central nervous system, GBM, DDR, United States Patent and Trademark Office, DHL, NHL, Traffic barrier, NSCLC, Prostate, Lung cancer, CNS, Glioblastoma, Actuate, Orange Book, Phase 10, BBB, Metadata, Permeability, Patient, Machine learning, Mantle cell lymphoma, Algorithm, Starlight, Cancer, MCL, Poster, AI, FDA, Therapy, PARP, IND, Food, D, Pharmaceutical industry, Medical imaging, Cryptocurrency, Olaparib, Lantern

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023.
  • First Quarter 2023 Financial Overview:
    Balance Sheet: Cash, cash equivalents, and marketable securities were approximately $51.5 million as of March 31, 2023, compared to approximately $55.2 million as of December 31, 2022.
  • G&A Expenses: General and administrative expenses were approximately $1.7 million for the quarter ended March 31, 2023, compared to approximately $1.4 million for the quarter ended March 31, 2022.
  • Earnings Call and Webinar Details:
    Lantern will host its first quarter 2023 earnings call and webinar today, Tuesday, May 9, 2023 at 4:30 p.m.

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Retrieved on: 
Monday, April 17, 2023
Orange County Convention Center, Panaveli, Bevacizumab, AACR, GAPDH, ATP, Quality of life, American Association for Cancer Research, Paclitaxel, Gynecologic Oncology (journal), Niraparib, Monroe Dunaway Anderson, Assistant, MD Anderson Cancer Center, HRMS, Olaparib, Patient, AKT, Translational research, University, Cancer, Ultra, MTT, HK2, Poster, Rucaparib, RNA interference, Reproductive medicine, Ovarian cancer, PARP, Therapy, Hand, Pharmaceutical industry

BERWYN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for the patients that receive them, today announced that positive data from the Company’s tumor cell selective and broadly active small molecule with a unique mechanism of action, GP-2250 (misetionamide), was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

Key Points: 
  • “The data generated by GP-2250 to date has continued to demonstrate promising treatment potential for cancers.
  • These findings are encouraging and provide valuable insight as we advance the development of GP-2250 for the treatment of ovarian cancer.
  • With this growing body of data, we look forward to further evaluating GP-2250’s potential in the treatment of ovarian cancer,” commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • Dr. Sood commented, “There remains a significant unmet need in treatment options for ovarian cancer.

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Ovarian cancer, DNA repair, Prostate cancer, NER, Rucaparib, Breast, Neoplasm, Prostate, Machine learning, HRR, DNA, Lung, Patient, Breast cancer, FDA, BRCA, PARP, Esophageal cancer, Stomach, Olaparib, Kidney, Pharmaceutical industry, Niraparib, Lantern

LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.

Key Points: 
  • LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.
  • The observations from these studies are further supported by in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern’s AI platform, RADR®.
  • “The combined anti-tumor potency of LP-100 in combination with PARP inhibitors, strongly supports the pursuit of this development pathway for LP-100,” stated Panna Sharma, Lantern’s President and CEO.
  • Lantern believes the simultaneous exploitation of both these mechanisms will enhance the development opportunities for LP-100, while also expanding potential market opportunities for existing PARP inhibitors.